AQST
Aquestive Therapeutics, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow +20.7% ·
net new positions +11.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | +3 | 39.01M | $162.27M | +5 | −2 |
| Q1 2026 | 71 | -4 | 39.34M | $163.45M | +7 | −11 |
| Q4 2025 | 75 | 0 | 41.69M | $269.29M | +1 | −1 |
| Q3 2025 | 16 | 0 | 21.57M | $120.55M | +1 | −1 |
| Q2 2025 | 13 | +1 | 18.15M | $60.07M | +1 | — |
| Q1 2025 | 9 | -2 | 4.86M | $14.09M | — | −2 |
| Q4 2024 | 11 | +1 | 4.40M | $15.68M | +1 | — |
| Q3 2024 | 9 | +1 | 3.11M | $15.51M | +2 | −1 |
| Q2 2024 | 8 | — | 2.58M | $6.65M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.67M | +5.7% | $8.31M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.67M | +5.7% | $8.31M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 871.83K | +419.5% | $4.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 871.83K | +419.5% | $4.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 185.19K | New | $922,251 | 0.0% | New | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 185.19K | New | $922,251 | 0.0% | New | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 133.79K | -2.1% | $666,284 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 130.80K | New | $651,384 | 0.0% | New | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 130.80K | New | $651,384 | 0.0% | New | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 41.30K | -54.5% | $205,679 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 31.05K | +204.7% | $154,609 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 28.60K | -94.2% | $142,428 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 23.85K | 0.0% | $119,000 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $922,251 | 0.0% |
| Wellington Management | $922,251 | 0.0% |
| AQR Capital Management | $651,384 | 0.0% |
| AQR Capital Management | $651,384 | 0.0% |
Exited
| Marshall Wace | $200,242 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 174 holders, 66.03M shares, $284.02M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 25.00K sh · $107,168
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology